Patrick Moss
Sarepta TherapeuticsAbout Patrick Moss
Patrick E. Moss, Pharm.D., is Executive Vice President and Chief Commercial Officer at Sarepta Therapeutics, appointed in July 2025 following his tenure leading U.S. Market Access and Sales . He joined Sarepta in 2015 as Director, Specialty Distribution & Payer Access, building market access, reimbursement, sales, and specialty distribution teams and helping oversee the launch of four Duchenne therapies, including EXONDYS 51 . He holds B.S. and Pharm.D. degrees from St. Louis College of Pharmacy and completed a Managed Care Pharmacy Residency at the University of Tennessee College of Pharmacy . Context for commercial performance during his tenure: preliminary Q2 2025 net product revenue of $513 million and an ELEVIDYS label update process; see revenue table below and ELEVIDYS update details .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Sarepta Therapeutics | Director, Specialty Distribution & Payer Access | 2015– | Built market access, reimbursement, sales, and specialty distribution teams; contributed to launch of four Duchenne therapies incl. EXONDYS 51 |
| Sarepta Therapeutics | EVP, Chief Commercial Officer | Appointed July 2025 | Leads commercial organization amid pipeline refocus and ELEVIDYS label update |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Incyte Corporation | Not disclosed | Not disclosed | Industry experience facilitating coverage of important medicines |
| Vertex Pharmaceuticals, Inc. | Not disclosed | Not disclosed | Commercial/market access experience |
| Amgen Inc. | Not disclosed | Not disclosed | Commercial/market access experience |
| Eli Lilly & Company | Not disclosed | Not disclosed | Commercial/market access experience |
Fixed Compensation
- No base salary or target bonus for Patrick Moss has been disclosed in the July 16, 2025 8-K or related press materials (the filing detailed compensation changes for other executives but did not provide Moss’s terms) .
Performance Compensation
- 2025 DEF 14A compensation tables list grants for named executive officers (NEOs) and board, not including Patrick Moss (who was appointed after the April 8, 2025 record date), and do not disclose Moss’s RSU/PSU or option award details .
Equity Ownership & Alignment
- The April 8, 2025 beneficial ownership table does not include Patrick Moss (appointment occurred in July 2025, after the record date) .
- Hedging prohibited: Sarepta’s Insider Trading Policy forbids hedging/monetization transactions for directors, officers, and employees .
- Stock ownership guidelines: Awards are subject to the Company’s Stock Ownership Guidelines for non-employee directors and executive officers .
Employment Terms
- Change-in-control and award treatment (plan-level terms): if outstanding awards are not assumed/substituted in a change in control, options/SARs become fully vested and exercisable and restrictions on restricted stock/RSUs lapse; performance goals on PSUs are deemed achieved at 100% of target .
- Clawback and ownership policies: all awards are subject to the Incentive Compensation and Equity Award Recoupment Policy and applicable ownership guidelines .
- Specific employment agreement, severance multiples, non-compete, or pledging status for Patrick Moss are not disclosed in available filings.
Performance & Track Record
Company revenues during the period surrounding Moss’s appointment:
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|
| Revenues ($USD) | $658,412,000 | $744,856,000 | $611,091,000 | $399,356,000 |
Additional context:
- Preliminary Q2 2025 net product revenue: $513 million; ELEVIDYS net product revenue $282 million; PMO net product revenue $231 million .
- ELEVIDYS label update: FDA-requested black box warning for ALI/ALF; enhanced immunosuppressive regimen proposed for non-ambulant patients (sirolimus) with plan to resume dosing via an ENDEAVOR Cohort 8 protocol submission .
Say-on-Pay & Shareholder Feedback
| Proposal | For | Against | Abstain | Broker Non-Votes |
|---|---|---|---|---|
| 2024 NEO compensation (advisory) | 72,144,292 | 2,176,998 | 62,710 | 10,202,114 |
Additional Signals
- Strategic restructuring: ~36% workforce reduction and a pipeline refocus toward siRNA programs; new commercial leadership (Moss) installed during this transition .
- Insider trading visibility: attempted Form 4 retrieval via insider-trades skill failed due to access error; thus, current insider transactions and post-appointment ownership for Moss remain unknown in these sources.
Investment Implications
- Alignment and governance: Strong company-level policies (hedging prohibition, ownership guidelines, clawback) support alignment; however, absence of disclosed Moss-specific compensation, vesting schedules, and severance terms limits pay-for-performance assessment and retention risk analysis .
- Execution risk and opportunity: Moss’s deep commercial/access background and history of launching Duchenne therapies could be additive as ELEVIDYS label evolves and the portfolio focuses on siRNA; revenue trends and Q2 net product performance provide a backdrop for near-term commercial KPIs .
- Monitoring priorities: Seek subsequent 8-Ks or proxy updates for Moss’s compensation package (base/bonus/RSU/PSU/option terms, performance metrics, and severance/CIC provisions), Form 4 filings for ownership and potential selling pressure, and commercial metrics tied to ELEVIDYS and PMO revenues to evaluate incentive alignment and performance trajectory.